In combination with azacitidine or decitabine, or very low-dose cytarabine in recently diagnosed AML aged ≥ 75 decades or with co-morbidities that preclude the usage of intense induction chemotherapy The photographs or other 3rd party material on this page are included in the posting’s Artistic Commons license, Except if indicated https://directivepublications.org/journal-of-leukemia-research/